Luminal B breast cancer: Molecular characterization, clinical management, and future perspectives

Journal of Clinical Oncology

Volumn 32, Issue 25, 2014, Pages 2794-2803

  Ades, Felipe ^a   Zardavas, Dimitrios ^b   Bozovic Spasojevic, Ivana ^c   Pugliano, Lina ^a   Fumagalli, Debora ^a   De Azambuja, Evandro ^a   Viale, Giuseppe ^d   Sotiriou, Christos ^a   Piccart, Martine ^a  

^a JULES BORDET INSTITUTE   (Belgium)

^b Breast International Group   (Belgium)

^c INSTITUTE FOR ONCOLOGY AND RADIOLOGY OF SERBIA   (Serbia)

^d UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIN DEPENDENT KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 1; HORMONE RECEPTOR; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SOMATOMEDIN; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

BASAL LIKE BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER PATIENT; CELL PROLIFERATION; DISEASE MARKER; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETIC SCREENING; HUMAN; LOSS OF FUNCTION MUTATION; LUMINAL A BREAST CANCER; LUMINAL B BREAST CANCER; POINT MUTATION; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SOMATIC MUTATION; TREATMENT RESPONSE; BREAST NEOPLASMS; CLASSIFICATION; FEMALE; GENETICS; METABOLISM; NEOPLASMS, HORMONE-DEPENDENT; PATHOLOGY; PROGNOSIS;

BREAST NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; NEOPLASMS, HORMONE-DEPENDENT; PHOSPHATIDYLINOSITOL 3-KINASE; PROGNOSIS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SIGNAL TRANSDUCTION;

EID: 84906805668     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.54.1870     Document Type: Review

References (126)

1. Perou CM, Sørlie T, Eisen MB, et al: Molecular portraits of human breast tumours. Nature 406: 747-752, 2000
2. Sørlie T, Perou CM, Tibshirani R, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98:10869-10874, 2001
3. Sorlie T, Tibshirani R, Parker J, et al: Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 100:8418-8423, 2003
4. Sotiriou C, Neo SY, McShane LM, et al: Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A 100:10393-10398, 2003
5. Brenton JD, Carey LA, Ahmed AA, et al: Molecular classification and molecular forecasting of breast cancer: Ready for clinical application? J Clin Oncol 23:7350-7360, 2005
6. Prat A, Cheang MCU, Martín M, et al: Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer. J Clin Oncol 31:203-209, 2013
7. Perou CM, Jeffrey SS, van de Rijn M, et al: Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc Natl Acad Sci U S A 96:9212-9217, 1999
8. Hu Z, Fan C, Oh DS, et al: The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 7:96, 2006
9. Wirapati P, Sotiriou C, Kunkel S, et al: Metaanalysis of gene expression profiles in breast cancer: Toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res 10:R65, 2008
10. Blows FM, Driver KE, Schmidt MK, et al: Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: A collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med 7:e1000279, 2010
11. Cheang MC, Chia SK, Voduc D, et al: Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 101:736-750, 2009
12. Goldhirsch A, Wood WC, Coates AS, et al: Strategies for subtypes:d Dealing with the diversity of breast cancer - Highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 22:1736- 1747, 2011
13. Harbeck N, Thomssen C, Gnant M: St. Gallen 2013: Brief preliminary summary of the consensus discussion. Breast Care (Basel) 8:102-109, 2013
14. Weinstein JN, Collisson EA, Mills GB, et al: The Cancer Genome Atlas pan-cancer analysis project. Nat Genet 45:1113-1120, 2013
15. Bergamaschi A, Kim YH, Wang P, et al: Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer. Genes Chromosomes Cancer 45:1033-1040, 2006
16. Chin K, DeVries S, Fridlyand J, et al: Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell 10:529-541, 2006
17. Sircoulomb F, Nicolas N, Ferrari A, et al: ZNF703 gene amplification at 8p12 specifies luminal B breast cancer. EMBO Mol Med 3:153-166, 2011
18. Holland DG, Burleigh A, Git A, et al: ZNF703 is a common luminal B breast cancer oncogene that differentially regulates luminal and basal progenitors in human mammary epithelium. EMBO Mol Med 3:167-180, 2011
19. Iwanaga R, Wang CA, Micalizzi DS, et al: Expression of Six1 in luminal breast cancers predicts poor prognosis and promotes increases in tumor initiating cells by activation of extracellular signalregulated kinase and transforming growth factorbeta signaling pathways. Breast Cancer Res 14: R100, 2012
20. Curtis C, Shah SP, Chin SF, et al: The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486:346-352, 2012
21. Cancer Genome Atlas Network: Comprehensive molecular portraits of human breast tumours. Nature 490:61-70, 2012
22. Ellis MJ, Ding L, Shen D, et al: Wholegenome analysis informs breast cancer response to aromatase inhibition. Nature 486:353-360, 2012
23. Banerji S, Cibulskis K, Rangel-Escareno C, et al: Sequence analysis of mutations and translocations across breast cancer subtypes. Nature 486: 405-409, 2012
24. Stender JD, Kim K, Charn TH, et al: Genomewide analysis of estrogen receptor alpha DNA binding and tethering mechanisms identifies Runx1 as a novel tethering factor in receptor-mediated transcriptional activation. Mol Cell Biol 30:3943-3955, 2010
25. Kadota M, Yang HH, Gomez B, et al: Delineating genetic alterations for tumor progression in the MCF10A series of breast cancer cell lines. PLoS ONE 5:e9201, 2010
26. Perreard L, Fan C, Quackenbush JF, et al: Classification and risk stratification of invasive breast carcinomas using a real-time quantitative RT-PCR assay. Breast Cancer Res 8:R23, 2006
27. Weigelt B, Mackay A, A'Hern R, et al: Breast cancer molecular profiling with single sample predictors: A retrospective analysis. Lancet Oncol 11: 339-349, 2010
28. Gnant M, Filipits M, Dubsky P: Predicting risk for late metastasis: The PAM50risk of recurrence (ROR) score after 5 years of endocrine therapy in postmenopausal women with HR+ early breast cancer - A study on 1,478 patients from the ABCSG-8 trial. Presented at the IMPAKT Breast Cancer Conference, Brussels, Belgium, May 2-4, 2013
29. Dowsett M, Sestak I, Lopez-Knowles E, et al: Comparison of PAM50 risk of recurrence score with Oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy. J Clin Oncol 31:2783-2790, 2013
30. Sotiriou C, Pusztai L: Gene-expression signatures in breast cancer. N Engl J Med 360:790-800, 2009
31. Collins LC, Botero ML, Schnitt SJ: Bimodal frequency distribution of estrogen receptor immunohistochemical staining results in breast cancer: An analysis of 825 cases. Am J Clin Pathol 123:16-20, 2005
32. Paik S, Shak S, Tang G, et al: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351: 2817-2826, 2004
33. Gerdes J, Lemke H, Baisch H, et al: Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 133:1710-1715, 1984
34. Dowsett M, Nielsen TO, A'Hern R, et al: Assessment of Ki67 in breast cancer: Recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst 103:1656-1664, 2011
35. de Azambuja E, Cardoso F, de Castro G Jr, et al: Ki-67 as prognostic marker in early breast cancer: A meta-analysis of published studies involving 12,155 patients. Br J Cancer 96:1504-1513, 2007
36. Bardou VJ, Arpino G, Elledge RM, et al: Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol 21:1973- 1979, 2003
37. Rakha EA, El-Sayed ME, Green AR, et al: Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype. J Clin Oncol 25:4772-4778, 2007
38. Cancello G, Maisonneuve P, Rotmensz N, et al: Progesterone receptor loss identifies luminal B breast cancer subgroups at higher risk of relapse. Ann Oncol 24:661-668, 2013
39. Nielsen TO, Parker JS, Leung S, et al: A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clin Cancer Res 16:5222-5232, 2010
40. Fan C, Oh DS, Wessels L, et al: Concordance among gene-expression-based predictors for breast cancer. N Engl J Med 355:560-569, 2006
41. Sotiriou C, Wirapati P, Loi S, et al: Gene expression profiling in breast cancer: Understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 98:262-272, 2006
42. Loi S, Haibe-Kains B, Desmedt C, et al: Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol 25:1239-1246, 2007
43. Fan C, Prat A, Parker JS, et al: Building prognostic models for breast cancer patients using clinical variables and hundreds of gene expression signatures. BMC Med Genomics 4:3, 2011
44. Venet D, Dumont JE, Detours V: Most random gene expression signatures are significantly associated with breast cancer outcome. PLoS Comput Biol 7:e1002240, 2011
45. Ignatiadis M, Bedard P, Haibe-Kains B, et al: A meta-analysis of gene expression profiling studies identifies clinically relevant oncogenic pathways in basal-like breast cancer. Cancer Res 69, 2009 (suppl 24; abstr 106)
46. Tran B, Bedard PL: Luminal-B breast cancer and novel therapeutic targets. Breast Cancer Res 13:221, 2011
47. Smid M, Wang Y, Zhang Y, et al: Subtypes of breast cancer show preferential site of relapse. Cancer Res 68:3108-3114, 2008
48. Paik S, Tang G, Shak S, et al: Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 24:3726-3734, 2006
49. Albain KS, Barlow WE, Shak S, et al: Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: A retrospective analysis of a randomised trial. Lancet Oncol 11:55-65, 2010
50. Gianni L, Zambetti M, Clark K, et al: Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol 23:7265-7277, 2005
51. Rouzier R, Perou CM, Symmans WF, et al: Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11:5678-5685, 2005
52. Carey LA, Dees EC, Sawyer L, et al: The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 13:2329-2334, 2007
53. de Ronde JJ, Hannemann J, Halfwerk H, et al: Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response. Breast Cancer Res Treat 119:119-126, 2010
54. Esserman LJ, Perou C, Cheang M, et al: Breast cancer molecular profiles and tumor response of neoadjuvant doxorubicin and paclitaxel: The I-SPY trial (CALGB 150007/150012, ACRIN 6657). J Clin Oncol 27:10s, 2009 (suppl; abstr LBA515)
55. Bhargava R, Beriwal S, Dabbs DJ, et al: Immunohistochemical surrogate markers of breast cancer molecular classes predicts response to neoadjuvant chemotherapy: A single institutional experience with 359 cases. Cancer 116:1431-1439, 2010
56. Lv M, Li B, Li Y, et al: Predictive role of molecularsubtypesinresponsetoneoadjuvantchemotherapy in breast cancer patients in Northeast China. Asian Pac J Cancer Prev 12:2411-2417, 2011
57. Straver ME, Glas AM, Hannemann J, et al: The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat 119:551-558, 2010
58. Lips EH, Mulder L, de Ronde JJ, et al: Neoadjuvant chemotherapy in ER+ HER2+ breast cancer: Response prediction based on immunohistochemical and molecular characteristics. Breast Cancer Res Treat 131:827-836, 2012
59. Ignatiadis M, Singhal SK, Desmedt C, et al: Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: A pooled analysis. J Clin Oncol 30:1996-2004, 2012
60. Peto R, Davies C, Godwin J, et al: Comparisons between different polychemotherapy regimens for early breast cancer: Meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 379:432-444, 2012
61. Cardoso F, Piccart-Gebhart M, Van't Veer L, et al: The MINDACT trial: The first prospective clinical validation of a genomic tool. Mol Oncol 1:246-251, 2007
62. Sparano JA: TAILORx: Trial assigning individualized options for treatment (Rx). Clin Breast Cancer 7:347-350, 2006
63. Gonzalez-Angulo AM, Barlow WE, Gralow J, et al: SWOG S1007: A phase III, randomized clinical trial of standard adjuvant endocrine therapy with or without chemotherapy in patients with one to three positive nodes, hormone receptor (HR)-positive, and HER2-negative breast cancer with recurrence score (RS) of 25 or less. J Clin Oncol 29:8s, 2011 (suppl; abstr TPS104)
64. Tamoxifen for early breast cancer: An overview of the randomised trials - Early Breast Cancer Trialists' Collaborative Group. Lancet 351:1451-1467, 1998
65. Viale G, Regan MM, Maiorano E, et al: Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. J Clin Oncol 25:3846-3852, 2007
66. Paik S, Shak S, Tang G, et al: Expression of the 21 genes in the recurrence score assay and tamoxifen clinical benefit in the NSABP study B-14 of node negative, estrogen receptor positive breast cancer. J Clin Oncol 23, 2005 (suppl; abstr 510)
67. Coombes RC, Kilburn LS, Snowdon CF, et al: Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): A randomised controlled trial. Lancet 369:559-570, 2007
68. Dowsett M, Cuzick J, Wale C, et al: Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: A TransATAC study. J Clin Oncol 28:1829-1834, 2010
69. Jansen MP, Foekens JA, van Staveren IL, et al: Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling. J Clin Oncol 23:732-740, 2005
70. Kok M, Linn SC, Van Laar RK, et al: Comparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifen. Breast Cancer Res Treat 113:275-283, 2009
71. Hugh J, Hanson J, Cheang MCU, et al: Breast cancer subtypes and response to docetaxel in node-positive breast cancer: Use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol 27:1168-1176, 2009
72. Dowsett M, Smith IE, Ebbs SR, et al: Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst 99:167-170, 2007
73. Ellis MJ, Tao Y, Luo J, et al: Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J Natl Cancer Inst 100:1380-1388, 2008
74. Dunbier AK, Anderson H, Ghazoui Z, et al: Association between breast cancer subtypes and response to neoadjuvant anastrozole. Steroids 76: 736-740, 2011
75. Miller TW, Balko JM, Arteaga CL: Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer. J Clin Oncol 29:4452-4461, 2011
76. Ellis MJ, Suman VJ, Hoog J, et al: Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: Clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype - ACOSOG Z1031. J Clin Oncol 29:2342-2349, 2011
77. Dowsett M, Cuzick J, Wale C, et al: Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: A hypothesis-generating study. J Clin Oncol 23:7512-7517, 2005
78. Viale G, Regan MM, Dell'Orto P, et al: Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial. Ann Oncol 22:2201-2207, 2011
79. Ellis MJ, Coop A, Singh B, et al: Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: Evidence from a phase III randomized trial. J Clin Oncol 19:3808-3816, 2001
80. Smith IE, Dowsett M, Ebbs SR, et al: Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: The Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol 23:5108-5116, 2005
81. De Laurentiis M, Arpino G, Massarelli E, et al: A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. Clin Cancer Res 11:4741-4748, 2005
82. Bose R, Kavuri SM, Searleman AC, et al: Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discov 3:224-237, 2013
83. Sleijfer S, Bogaerts J, Siu LL: Designing transformative clinical trials in the cancer genome era. J Clin Oncol 31:1834-1841, 2013
84. Miller TW, Hennessy BT, González-Angulo AM, et al: Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer. J Clin Invest 120:2406-2413, 2010
85. Miller TW, Pérez-Torres M, Narasanna A, et al: Loss of phosphatase and tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancer. Cancer Res 69:4192-4201, 2009
86. Massarweh S, Osborne CK, Creighton CJ, et al: Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res 68:826-833, 2008
87. Juncker-Jensen A, Lykkesfeldt AE, Worm J, et al: Insulin-like growth factor binding protein 2 is a marker for antiestrogen resistant human breast cancer cell lines but is not a major growth regulator. Growth Horm IGF Res 16:224-239, 2006
88. Zardavas D, Fumagalli D, Loi S: Phosphatidylinositol 3-kinase/AKT/ mammalian target of rapamycin pathway inhibition: A breakthrough in the management of luminal (ER+/HER2+) breast cancers? Curr Opin Oncol 24:623-634, 2012
89. Loi S, Haibe-Kains B, Majjaj S, et al: PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer. Proc Natl Acad Sci U S A 107:10208-10213, 2010
90. Awada A, Cardoso F, Fontaine C, et al: The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: Results of a phase I study with pharmacokinetics. Eur J Cancer 44:84-91, 2008
91. Baselga J, Semiglazov V, van Dam P, et al: Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol 27:2630-2637, 2009
92. Bachelot T, Bourgier C, Cropet C, et al: Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor- positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: A GINECO study. J Clin Oncol 30:2718-2724, 2012
93. Baselga J, Campone M, Piccart M, et al: Everolimus in postmenopausal hormone-receptorpositive advanced breast cancer. N Engl J Med 366:520-529, 2012
94. Hortobagyi GN, Piccart MJ, Rugo HS, et al: Correlation of molecular alterations with efficacy of everolimus in hormone receptor-positive, HER2- negative advanced breast cancer: Results from BOLERO-2. J Clin Oncol 31, 2013 (suppl 15s; abstr LBA509)
95. Loi S, Michiels S, Baselga J, et al: PIK3CA genotype and a PIK3CA mutation-related gene signature and response to everolimus and letrozole in estrogen receptor positive breast cancer. PLoS ONE 8:e53292, 2013
96. Bachelot T, Ferrero J, Cropet C, et al: Translational studies within the TAMRAD randomized Gineco trial: Evidence for TORC1 activation marker as a predictive factor for everolimus efficacy in metastatic breast cancer (MBC). Presented at the IMPAKT Breast Cancer Conference, Brussels, Belgium, May 3-5, 2012
97. Choo AY, Blenis J: Not all substrates are treated equally: Implications for mTOR, rapamycinresistance and cancer therapy. Cell Cycle 8:567-572, 2009
98. Harrington LS, Findlay GM, Gray A, et al: The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J Cell Biol 166:213-223, 2004
99. Zardavas D, Baselga J, Piccart M: Emerging targeted agents in metastatic breast cancer. Nat Rev Clin Oncol 10:191-210, 2013
100. Turner N, Grose R: Fibroblast growth factor signalling: From development to cancer. Nat Rev Cancer 10:116-129, 2010
101. Turner N, Pearson A, Sharpe R, et al: FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res 70:2085-2094, 2010
102. Elbauomy Elsheikh S, Green AR, Lambros MB, et al: FGFR1 amplification in breast carcinomas: A chromogenic in situ hybridisation analysis. Breast Cancer Res 9:R23, 2007
103. Dienstmann R, Andre F, Soria J, et al: 319O: Significant antitumor activity of E-3810, a novel FGFR and VEGFR inhibitor, in patients with FGFR1 amplified breast cancer. Presented at the European Society for Medical Oncology Congress, Vienna, Austria, September 28-October 2, 2012
104. Andre F, Bachelot T, Campone M, et al: A multicenter, open-label phase II trial of dovitinib, a fibroblast growth factor receptor 1 (FGFR1) inhibitor, inFGFR1-amplified and nonamplified metastatic breast cancer (BC). J Clin Oncol 29, 2011 (suppl; abstr 289)
105. Pollak M: The insulin and insulin-like growth factor receptor family in neoplasia: An update. Nat Rev Cancer 12:159-169, 2012
106. Clarke RB, Howell A, Anderson E: Type I insulin-like growth factor receptor gene expression in normal human breast tissue treated with oestrogen and progesterone. Br J Cancer 75:251-257, 1997
107. Hamelers IH, van Schaik RF, van Teeffelen HA, et al: Synergistic proliferative action of insulinlike growth factor I and 17 beta-estradiol in MCF-7S breast tumor cells. Exp Cell Res 273:107-117, 2002
108. Wiseman LR, Johnson MD, Wakeling AE, et al: Type I IGF receptor and acquired tamoxifen resistance in oestrogen-responsive human breast cancer cells. Eur J Cancer 29A:2256-2264, 1993
109. Parisot JP, Hu XF, DeLuise M, et al: Altered expression of the IGF-1 receptor in a tamoxifenresistant human breast cancer cell line. Br J Cancer 79:693-700, 1999
110. Lisztwan J, Pornon A, Chen B, et al: The aromatase inhibitor letrozole and inhibitors of insulin-like growth factor I receptor synergistically induce apoptosis in in vitro models of estrogendependent breast cancer. Breast Cancer Res 10: R56, 2008
111. Hou X, Huang F, Macedo LF, et al: Dual IGF- 1R/InsR inhibitor BMS-754807 synergizes with hormonal agents in treatment of estrogen-dependent breast cancer. Cancer Res 71:7597-7607, 2011
112. Kaufman P, Ferrero J, Bourgeois H, et al: A randomized, double-blind, placebo-controlled, phase 2 study of AMG 479 with exemestane (E) or fulvestrant (F) in postmenopausal women with hormonereceptor positive (HR+) metastatic (M) or locally advanced (LA) breast cancer (BC). Cancer Res 70, 2011 (abstr S1-4)
113. Di Cosimo S, Bendell JC, Cervantes-Ruiperez A, et al: A phase I study of the oral mTOR inhibitor ridaforolimus (RIDA) in combination with the IGF-1R antibody dalotozumab (DALO) in patients (pts) with advanced solid tumors. J Clin Oncol 28:235s, 2010 (suppl; abstr 3008)
114. O'Reilly KE, Rojo F, She QB, et al: MTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 66:1500-1508, 2006
115. Musgrove EA, Caldon CE, Barraclough J, et al: Cyclin D as a therapeutic target in cancer. Nat Rev Cancer 11:558-572, 2011
116. Stendahl M, Kronblad A, Rydén L, et al: Cyclin D1 overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients. Br J Cancer 90:1942-1948, 2004
117. Rudas M, Lehnert M, Huynh A, et al: Cyclin D1 expression in breast cancer patients receiving adjuvant tamoxifen-based therapy. Clin Cancer Res 14:1767-1774, 2008
118. Span PN, Tjan-Heijnen VC, Manders P, et al: Cyclin-E is a strong predictor of endocrine therapy failure in human breast cancer. Oncogene 22:4898-4904, 2003
119. Caldon CE, Sergio CM, Kang J, et al: Cyclin E2 overexpression is associated with endocrine resistance but not insensitivity to CDK2 inhibition in human breast cancer cells. Mol Cancer Ther 11: 1488-1499, 2012
120. Finn R, Crown J, Boer K, et al: Results of a randomized phase 2 study of PD 0332991, a cyclindependent kinase (CDK) 4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER+, HER2+ advanced breast cancer (TRIO-18). Presented at the IMPAKT Breast Cancer Conference, Brussels, Belgium, May 3-5, 2012
121. Shangary S, Wang S: Targeting the MDM2- p53 interaction for cancer therapy. Clin Cancer Res 14:5318-5324, 2008
122. Rabello Ddo A, de Moura CA, de Andrade RV, et al: Altered expression of MLL methyltransferase family genes in breast cancer. Int J Oncol 43:653-660, 2013
123. Rodríguez-Paredes M, Esteller M: Cancer epigenetics reaches mainstream oncology. Nat Med 17:330-339, 2011
124. Zhou Q, Atadja P, Davidson NE: Histone deacetylase inhibitor LBH589 reactivates silenced estrogen receptor alpha (ER) gene expression without loss of DNA hypermethylation. Cancer Biol Ther 6:64-69, 2007
125. Hostetter CL, Licata LA, Keen JC: Timing is everything: Order of administration of 5-aza 2+ deoxycytidine, trichostatin A and tamoxifen changes estrogen receptor mRNA expression and cell sensitivity. Cancer Lett 275:178-184, 2009
126. Yardley DA, Ismail-Khan RR, Melichar B, et al: Randomized phase II, double-blind, placebocontrolled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor. J Clin Oncol 31:2128-2135, 2013